Science1 publisherNot yet confirmed elsewhere2 min readPublished
Structures show bacteria turn on LPS transport only after the trans-envelope bridge assembles
A Nature study presents three structures of the bacterial LPS delivery machine showing it switches on transport only once its bridge assembles and senses LPS. The outer membrane it builds blocks many antibiotics, making bridge assembly a possible point of attack in Gram-negative bacteria.
The Scientist · Science desk
What happened
- Assembling the bridge shifts a single transmembrane helix of LptC when LPS is present, and that shift increases the ATP binding and hydrolysis that power transport.
- The team solved the bridge in three states, with no LPS, with LPS bound and with ATP bound, plus a separate structure of a partial bridge.
- Intact bridges came apart when pulled from cells, so the structures came from complexes rebuilt in a test tube from separately purified parts.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- capability The LPS layer blocks many drugs that kill Gram-positive bacteria, so a compound that stopped bridge assembly or held the LptC helix in its off position would hit a defense those drugs cannot cross.
- constraint The authors hold that only the longer-lived of two bridge types actually transports LPS, so an effective inhibitor would have to act on the assembled, active state and not merely on loose components.
- precedent Framing transport as a switch that LPS turns on makes the LPS-free, off-state bridge a defined target to screen compounds against.
The inner membrane is where LPS is made, and letting it build up there is toxic, so bacteria already limit how much they synthesize [3]. Whether they also control the rate at which LPS crosses to the outer membrane [2] had been an open question [4]. The structures argue that they do [8].
The model the authors propose is a coordination circuit. An assembled bridge senses LPS at the inner membrane and responds by moving the transmembrane helix of LptC, which raises ATP binding and hydrolysis and turns transport on [6][8]. A bridge spanning the whole envelope links an inner-membrane ABC transporter, LptB2FGC, a periplasmic protein, LptA, and an outer-membrane translocon, LptDE, into one continuous conduit [10][11], powered by ATP in the cytoplasm [12].
The claim rests on more than static pictures. In living cells, moving LPS required both that the bridge form and that the LptC helix move; block either and transport stops [7].
Capturing the complex was not straightforward. Bridges pulled straight from cells fell apart during purification, so the team rebuilt them in vitro from separately purified parts [14]. The structures used a version in which LptC and LptA are fused into one chain by a flexible linker, a construct that forms sturdier bridges than the wild type [15]. That engineered stability is both why the pictures exist and a condition on reading them.
The outer membrane this pathway builds is why Gram-negative infections resist so many drugs: its LPS layer shuts out many antibiotics that kill Gram-positive bacteria [9][1]. A control point is a more specific thing to aim at than a whole essential pathway. The paper does not provide a drug, a druggable pocket, or evidence that freezing the LptC helix inside a pathogen is achievable; it identifies where the switch sits and does not test whether that switch can be blocked [6].
What to watch
- Whether any compound can block bridge assembly or trap the LptC helix in its off state inside a living pathogen.
- Whether the engineered LptC-LptA fusion behaves like wild-type bridges, or whether the linker shapes what the structures show.
- Whether the same LPS-triggered switch operates across other Gram-negative pathogens.